We are driving toward meaningful, positive change in the world in a way that is both market-sustainable and profitable. Specifically, we are working to expand surgical access for some of the 5 billion people around the world who currently can't get surgery when they need it, in large part due to the complexity and infrastructure cost of delivering currently available general anesthetics.
At the same time, Expanesthetics exists to generate a risk-adjusted return on investment for its shareholders. We envision achieving this by expanding the market for inhaled general anesthetics through the development of new agents with fewer side effects and new beneficial effects.
The first two-thirds of the twentieth century was an exciting era of innovation in inhaled general anesthetic development. Sadly, the industry has been largely stagnant for half a century since the revolutionary innovations of the 1960s and 70s. Expanesthetics is leading the way toward a new era of revolutionary advances.
Most of the companies that drove the mid-20th century's innovations are either gone or have been absorbed into large, diversified drug or device companies that invest only in commercial-stage assets. But a small handful of private and public companies remain independent and retain the capacity and culture to invest and innovate in this space. Expanesthetics' current priority is to collaborate with them to advance the next generation of inhaled general anesthetics.
Expanesthetics is based on groundbreaking science at the forefront of anesthetic research. Dr. Robert Brosnan, the inventor behind our technology, is the student and academic heir of Ted Eger, industry luminary and contemporary of other 20th century leaders such as Ross Terrell. Dr. Brosnan's discovery gives Expanesthetics a path for developing new inhaled general anesthetics with fewer side effects and new beneficial effects.
Our foundational research has yielded multiple proof-of-concept candidates with compelling characteristics like cardiovascular stability and potential for native analgesia.
Over 100 anesthesiologists have invested in Expanesthetics, and the company is run by an experienced team of business, clinical, and research leaders. These include luminaries in the field of anesthesia, people who have managed billion-dollar enterprises, and leaders in both public and private companies.
"As an acute pain and regional anesthesiologist, my practice focuses on advancing clinical anesthesia. I joined the Expanesthetics team as a shareholder because I see the potential for the technology to create incredibly positive change not only for my practice, but for the practice of anesthesia around the world."
Chauncey T. Jones, MD
Anesthesiologist and Business Owner
Houston, TX
